Antidiabetic Drugs for Steatotic Liver Disease

Exclusion Criteria

• •1. Type 1 diabetes and gestational diabetes
• •2. Highly uncontrolled diabetes (HbA1c ≥ 11.0%)
• •3. Excessive alcohol intake (210 g and 140 g/week for men and women, respectively) within the previous 2 years
• •4. A history of taking thiazolidinedione or sodium-glucose cotransporter 2 inhibitor class medications within the last 12 weeks, or a history of discontinuing these medications due to severe side effects
• •5. Treatment with four or more classes of antidiabetic medications
• •6. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, within 24 weeks
• •7. Intake of drugs that can cause steatotic liver disease (amiodarone, methotrexate, tamoxifen, valproate, etc.)
• •8. Allergy or hypersensitivity to the study drugs or their constituents
• •9. Oral or parenteral chronic corticosteroid therapy (more than 14 consecutive days) that requires continual adjustments in corticosteroid dose for therapeutic purposes within 8 weeks
• •10. Galactosemia
• •11. Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• •12. Malignant tumors currently undergoing treatment or progression
• •13. A history of substance abuse or alcohol intoxication within 12 weeks
• •14. Infection of human immunodeficiency virus
• •15. Severe infection
• •16. Pre- and post-operative status, or severe trauma
• •17. Cardiac failure within 24 weeks (class III to IV in the NYHA classification)
• •18. Acute cardiovascular event within 12 weeks (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or coronary intervention)
• •19. AAcute and chronic renal disease (estimated glomerular filtration rate \< 45 mL/min/1.73 m²) or dialysis
• •20. Pregnant or lactating women
• •21. Individuals whom the investigator determines to be unsuitable for participation in the clinical trial